Etomidate can be recommended for short procedures combined with fentanyl and for the induction of neuroleptanesthesia. It has advantages in poor risk patients because it has only negligible effects on the heart and the peripheral circulation. It has to taken in consideration though, that etomidate has only hypnotic and no analgesic action.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Hypotension after induction of anesthesia with remimazolam or etomidate: a non-inferiority randomized controlled trial in patients undergoing coronary artery bypass grafting.
Korean J Anesthesiol
January 2025
Department of Anaesthesiology and Pain Medicine, Samsung Medical Centre, Sungkyukwan University School of Medicine, Seoul, Republic of Korea.
Background: Remimazolam is a novel ultra-short-acting benzodiazepine known for its hemodynamic stability over propofol. However, its hemodynamic effects compared to those of etomidate are not well established. This study aimed to determine whether the use of remimazolam is non-inferior to etomidate with regard to the occurrence of post-induction hypotension in patients undergoing coronary arterial bypass grafting.
View Article and Find Full Text PDFIs there still a place for etomidate in the management of Cushing's syndrome? The experience of a single center of low-dose etomidate and combined etomidate-osilodrostat treatment in severe hypercortisolemia.
Endocrine
December 2024
Department of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw, Warsaw, Poland.
Purpose: Severe Cushing's syndrome (SCS) is a life-threatening endocrine condition that requires prompt medical intervention. Intravenous etomidate infusion is considered to be the most effective in rapid cortisol overproduction inhibition. This single-center retrospective study aimed to present the safety and effectiveness of intravenous, low-dose, lipid-formulated etomidate infusion in patients with SCS.
View Article and Find Full Text PDFEfficacy and safety of remimazolam tosylate for patients undergoing off-pump coronary artery bypass grafting: a study protocol for a non-inferiority randomised controlled trial in China.
BMJ Open
November 2024
Department of Anaesthesiology, Zibo Central Hospital, Zibo, Shandong, China
Introduction: Maintaining haemodynamic stability is crucial but challenging during the induction and maintenance of general anaesthesia (GA) in patients undergoing off-pump coronary artery bypass grafting (OPCABG). Remimazolam tosylate is a novel ultra-short-acting benzodiazepine with minimal cardiovascular depression. Currently, non-inferior studies comparing the haemodynamic changes induced by remimazolam and etomidate are limited.
View Article and Find Full Text PDFBehavioral studies of the abuse potential and anesthetic and sedative effects of etomidate in male rodents.
Psychopharmacology (Berl)
November 2024
Office of China National Narcotics Control Commission, China Pharmaceutical University Joint Laboratory on Key Technologies of Narcotics Control, Beijing, China, 100193.
Article Synopsis
- Etomidate is a short-acting anesthetic gaining attention due to its potential for abuse, especially when mixed in e-cigarettes, yet it has not been researched for its abuse potential until now.
- This study used tests on male mice and rats to evaluate etomidate's rewarding and reinforcing effects, finding that specific doses caused conditioned place preference and led to the self-administration of the drug.
- Results indicate that etomidate has significant abuse potential in rodents, demonstrating rewarding effects, which raises concerns about its possible abuse in humans.
Phase 1 single-centre placebo- and etomidate-controlled study in healthy volunteers to assess safety, tolerability, clinical effects, and pharmacokinetics of intravenous methoxyethyl etomidate hydrochloride (ET-26).
Br J Anaesth
January 2025
Department of Anaesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China. Electronic address:
Background: Methoxyethyl etomidate hydrochloride (ET-26) is a novel etomidate analogue. This is the first-in-human study of a bolus i.v.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!